Faes Farma, S.A. (BME:FAE)

Spain · Delayed Price · Currency is EUR

4.790

+0.005 (0.10%)

Apr 28, 2026, 5:35 PM CET

15.28% (1Y)

Market Cap	1.49B
Revenue (ttm)	626.99M
Net Income (ttm)	79.63M
Shares Out	311.26M
EPS (ttm)	0.25
PE Ratio	18.86
Forward PE	15.70
Dividend	0.18 (3.74%)
Ex-Dividend Date	Jan 8, 2026

Volume	105,887
Average Volume	124,279
Open	4.780
Previous Close	4.785
Day's Range	4.735 - 4.810
52-Week Range	4.100 - 5.440
Beta	0.32
RSI	48.14
Earnings Date	Apr 30, 2026

About Faes Farma

Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal plants services, as well as acquiring, purchasing, disposing of, investing in, holding, using, managing, administering, marketing and leasing corporations, securiti... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1933

Employees 2,681

Stock Exchange Madrid Stock Exchange

Ticker Symbol FAE

Full Company Profile

Financial Performance

In 2025, Faes Farma's revenue was 626.99 million, an increase of 22.93% compared to the previous year's 510.04 million. Earnings were 79.63 million, a decrease of -28.49%.

Financial Statements

News

Faes Farma Earnings Call Transcript: Q4 2025

2025 saw 23% revenue growth, major acquisitions, and strong international expansion, with adjusted EBITDA up 3.1% and net profit down due to one-offs. 2026 guidance targets 17%-19% revenue and 28%-31% EBITDA growth, with continued focus on integration, efficiency, and international markets.

2 months ago - Transcripts

Faes Farma Transcript: M&A Announcement

The acquisition of SIFI accelerates the 2030 growth strategy, expanding the ophthalmology portfolio, global reach, and R&D pipeline. The €270 million deal is expected to be EPS accretive from year one, with strong synergies, high-margin businesses, and limited competition in key areas.

11 months ago - Transcripts

Faes Farma Transcript: CMD 2025

A new leadership team has set an ambitious plan to double sales and nearly double EBITDA by 2030, driven by international expansion, innovation, and targeted M&A. Key investments in R&D, operational excellence, and a new plant support growth, while a renewed culture and sustainability are central to the strategy.

1 year ago - Transcripts